Colonic transendoscopic tube-delivered enteral therapy (with video): a prospective study.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
06 May 2020
Historique:
received: 26 05 2019
accepted: 27 04 2020
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 20 2 2021
Statut: epublish

Résumé

Colonic transendoscopic enteral tubing (TET) refers to colonic transendoscopic tube-delivered enteral therapy. Colonic TET has been successfully used for frequent colonic administration of drugs or multiple fecal microbiota transplantations (FMTs). This prospective observational study aimed to evaluate possible factors affecting methodology, feasibility and safety of colonic TET. Patients who underwent colonic TET at our center from October 2014 to November 2018 were included. The feasibility, efficacy, and safety of TET were evaluated. In total, 224 patients were analyzed. The success rate of TET was 100%. The median retention time of TET tube within the colonic lumen was 8.5 (IQR 7-11) days in 158 patients with tube falling out spontaneously, and the maximum retention time was up to 28 days. These patients were divided into the short-retention group (≤ 8.5 days) and the long-retention group (> 8.5 days). Univariate and multivariate analysis demonstrated that the type of endoscopic clip (p = 0.001) was an independent factor for the retention time. The larger clips as well as a greater number of clips significantly affected the retention time (p = 0.013). No severe adverse event was observed during and after TET. Colonic TET is a feasible, practical, and safe colon-targeted drug delivery technique with a high degree of patients' satisfaction. Two to four large endoscopic clips are recommended to maintain stability of the TET tube within the colon for over 7 days.

Sections du résumé

BACKGROUND BACKGROUND
Colonic transendoscopic enteral tubing (TET) refers to colonic transendoscopic tube-delivered enteral therapy. Colonic TET has been successfully used for frequent colonic administration of drugs or multiple fecal microbiota transplantations (FMTs). This prospective observational study aimed to evaluate possible factors affecting methodology, feasibility and safety of colonic TET.
METHODS METHODS
Patients who underwent colonic TET at our center from October 2014 to November 2018 were included. The feasibility, efficacy, and safety of TET were evaluated.
RESULTS RESULTS
In total, 224 patients were analyzed. The success rate of TET was 100%. The median retention time of TET tube within the colonic lumen was 8.5 (IQR 7-11) days in 158 patients with tube falling out spontaneously, and the maximum retention time was up to 28 days. These patients were divided into the short-retention group (≤ 8.5 days) and the long-retention group (> 8.5 days). Univariate and multivariate analysis demonstrated that the type of endoscopic clip (p = 0.001) was an independent factor for the retention time. The larger clips as well as a greater number of clips significantly affected the retention time (p = 0.013). No severe adverse event was observed during and after TET.
CONCLUSIONS CONCLUSIONS
Colonic TET is a feasible, practical, and safe colon-targeted drug delivery technique with a high degree of patients' satisfaction. Two to four large endoscopic clips are recommended to maintain stability of the TET tube within the colon for over 7 days.

Identifiants

pubmed: 32375675
doi: 10.1186/s12876-020-01285-0
pii: 10.1186/s12876-020-01285-0
pmc: PMC7203978
doi:

Substances chimiques

Gastrointestinal Agents 0

Types de publication

Journal Article Observational Study Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

135

Subventions

Organisme : National Natural Science Foundation of China
ID : 81670495
Organisme : National Natural Science Foundation of China
ID : 81600417
Organisme : Jiangsu Province Creation Team and Leading Talents project
ID : -
Organisme : Top-notch Talent Research Projects
ID : LGY2017080
Organisme : public donated Intestine Initiative Foundation
ID : -

Références

Infection. 2012 Dec;40(6):643-8
pubmed: 22847629
Clin Infect Dis. 2014 Jun;58(11):1515-22
pubmed: 24762631
World J Clin Cases. 2019 Oct 6;7(19):3074-3081
pubmed: 31624757
Endosc Int Open. 2016 Jun;4(6):E610-3
pubmed: 27556065
Aliment Pharmacol Ther. 2015 Aug;42(4):470-6
pubmed: 26096320
Gut Liver. 2016 Nov 15;10(6):975-980
pubmed: 27282271
J Clin Gastroenterol. 2016 Nov/Dec;50(10):865-870
pubmed: 26751143
Protein Cell. 2018 May;9(5):462-473
pubmed: 29691757
Clin Microbiol Infect. 2017 May;23(5):337.e1-337.e3
pubmed: 28057560
Kaohsiung J Med Sci. 2019 Sep;35(9):566-571
pubmed: 31197926
Gut. 2018 Nov;67(11):1920-1941
pubmed: 30154172
Aliment Pharmacol Ther. 2019 Aug;50(3):240-248
pubmed: 31136009
Drug Saf. 2019 Jul;42(7):869-880
pubmed: 30972640
Protein Cell. 2020 Apr;11(4):251-266
pubmed: 31919742
Adv Ther. 2018 Nov;35(11):1935-1944
pubmed: 30328062
Aliment Pharmacol Ther. 2012 Sep;36(6):503-16
pubmed: 22827693
BMC Gastroenterol. 2018 Mar 13;18(1):37
pubmed: 29534703
Appl Microbiol Biotechnol. 2019 Jan;103(1):349-360
pubmed: 30357440
J Gastroenterol Hepatol. 2015 Jan;30(1):51-8
pubmed: 25168749
Nat Med. 2018 Dec;24(12):1804-1808
pubmed: 30420754
Clin Infect Dis. 2018 Mar 19;66(7):987-994
pubmed: 29562266
Crit Care. 2019 Oct 21;23(1):324
pubmed: 31639033
Am J Gastroenterol. 2019 Jul;114(7):1071-1079
pubmed: 30730351
Aliment Pharmacol Ther. 2018 Jul;48(2):152-159
pubmed: 29851107
United European Gastroenterol J. 2018 Oct;6(8):1232-1244
pubmed: 30288286
J Dig Dis. 2019 Aug;20(8):401-408
pubmed: 31070838
J Transl Med. 2015 Sep 12;13:298
pubmed: 26363929
JAMA. 2019 Jan 15;321(2):156-164
pubmed: 30644982
J Crohns Colitis. 2014 Dec;8(12):1569-81
pubmed: 25223604
Lancet. 2017 Mar 25;389(10075):1218-1228
pubmed: 28214091

Auteurs

Ting Zhang (T)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China.

Chuyan Long (C)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.

Bota Cui (B)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China.

Heena Buch (H)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China.

Quan Wen (Q)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China.

Qianqian Li (Q)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China.

Xiao Ding (X)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China.

Guozhong Ji (G)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China.

Faming Zhang (F)

Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China. fzhang@njmu.edu.cn.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China. fzhang@njmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH